United States Clinical Trials Market Size, Share and Outlook - Growth Analysis Report and Forecast Trends (2026-2035)

The United States clinical trials market was valued at USD 27.89 Billion in 2025 and is expected to grow at a CAGR of 6.80%, reaching USD 53.85 Billion by 2035. The market growth is driven by increasing research and development activities and investment in novel therapeutics.

Latest News on the United States Clinical Trials Market (2026)

April 2026: AACR Study Reveals Phase I NSCLC Trial Site Decline

A study presented at the American Association for Cancer Research Annual Meeting in April 2026 revealed that unique Phase I non-small cell lung cancer trial sites in the United States declined by approximately 44 percent between 2020 and 2024, raising concerns about geographic consolidation and patient access. As covered by The ASCO Post, the findings highlight emerging access barriers reshaping the U.S. clinical trials landscape.

March 2026: ClinicalTrials.gov Sees Strong Surge in U.S. Trial Registrations Nationwide

Federal registry data tracked through the U.S. National Library of Medicine showed sustained momentum in March 2026, with hundreds of new clinical trials registered and more than 22,000 studies actively recruiting participants across the country. The figures published on ClinicalTrials.gov reflect continued pharmaceutical and biotech investment, signaling robust pipeline activity across oncology, cardiology, immunology, and rare disease research segments within the United States clinical trials market.

Q1 2026 Market Updates

The Iran-US-Israel conflict that escalated on February 28, 2026, is creating indirect but meaningful disruptions for the United States clinical trials market, valued at approximately USD 43.85 billion in 2025 and projected to grow at a CAGR of 6.30% through 2030. The conflict has driven up pharmaceutical raw material costs by 5-100% and disrupted global logistics corridors, affecting the supply of investigational drugs, biological samples, and clinical trial supplies that must move through international networks. The Strait of Hormuz closure and 79% reduction in Gulf air-cargo capacity have complicated the movement of temperature-sensitive clinical materials across global trial sites.

Clinical trials increasingly operate across multiple countries, and the conflict's disruption of Middle Eastern air hubs affects the transportation of biological specimens, investigational medicinal products, and laboratory reagents between US-based sponsors and international trial sites. Contract research organizations managing multi-regional trials face logistical challenges in maintaining protocol timelines when shipping routes through Gulf corridors are compromised. The semiconductor-grade helium shortage - following the attack on Qatar's Ras Laffan facility - also threatens the availability of advanced diagnostic and imaging equipment used in clinical trial assessments.

Rising energy costs and inflationary pressures from the conflict are increasing operational expenses for clinical trial sites, CROs, and pharmaceutical sponsors. Oil prices surging approximately 45% since late February translate into higher transportation, laboratory operations, and facility costs. The broader economic uncertainty may also affect pharmaceutical companies' investment decisions regarding new trial initiations, potentially delaying pipeline development. However, the growing demand for personalized medicine and rising chronic disease prevalence continue to support fundamental market growth drivers.

The US clinical trials sector's strong domestic infrastructure and regulatory framework provide resilience, but the conflict underscores the importance of supply chain diversification for trial materials. Decentralized trial models using remote monitoring and telemedicine are gaining additional relevance as alternatives to traditional site-based approaches that depend heavily on international logistics networks.